<DOC>
	<DOC>NCT01128556</DOC>
	<brief_summary>To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.</brief_summary>
	<brief_title>The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing</brief_title>
	<detailed_description />
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>Healthy male and female subjects, 18 to 65 years of age Patients must demonstrate a positive reaction to a Histamine skinprick test. Manifested by a histamineinduced wheal of &gt;3mm in diameter over the normal saline control after 15 minutes of elapsed time Significant signs and symptoms of currently active allergic disease (SAR, perennial allergic rhinitis, episodic allergic rhinitis) Upper respiratory tract infection, sinusitis, asthma or flulike symptoms within 2 weeks prior to visit 1 Subjects who have dermatographism or other skin conditions which might interfere with the interpretation of the skin test results Subjects who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy Known hypersensitivity to the investigational product or to drugs with similar chemical properties Pregnancy and/or breast feeding Use of antihistamines, NSAIDS, steroids, or other drugs which may affect the skinresponse Use of any medications or agents that are not specified above that may confound the interpretation of the results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>allergic conjunctivitis</keyword>
	<keyword>histamine skin testing</keyword>
</DOC>